[1] |
Yamada H, Gursel I, Takeshita F, et al. Effect of suppressive DNA on CpG-induced immune activation[J]. J Immunol, 2002, 169(10): 5590-5594.
|
[2] |
Boehm O, Markowski P, van der Giet M, et al. In vivo TLR9 inhibition attenuates CpG-induced myocardial dysfunction[J]. Mediators Inflamm, 2013, 2013: 217297.
|
[3] |
Zhang Y, Zhu X, Feng Y, et al. TLR4 and TLR9 signals stimulate protective immunity against blood-stage Plasmodium yoelii infection in mice[J]. Exp Parasitol, 2016, 170: 73-81.
|
[4] |
胡坤, 王国玮, 王振海. HCV刺激小胶质细胞后TLR9蛋白的表达及其与MCP-1, TNF-α的关系[J]. 细胞与分子免疫学杂志, 2011, 27(10): 1083-1085.
|
[5] |
杨雪姣, 刘万成, 祝元锋, 等. CpG-c41对TLR9信号通路的干扰作用及其机制探究[J]. 免疫学杂志, 2016, 32(12): 1024-1028.
|
[6] |
周庆, 郝璐, 周泽强. 固有免疫系统Toll样受体的研究进展[J]. 生物学杂志, 2016, 33(3): 83-87.
|
[7] |
李松, 车南颖, 张林波, 等. Toll样受体在结核病免疫应答中的作用[J]. 结核病与胸部肿瘤, 2010, 22(3): 218-222.
|
[8] |
Zhou Y, Fang L, Peng L, et al. TLR9 and its signaling pathway in multiple sclerosis[J]. J Neurol Sci, 2017, 373: 95-99.
|
[9] |
Chen JQ, Szodoray P, Zeher M.Toll-like receptor pathways in autoimmune diseases[J]. Clin Rev Allergy Immunol, 2016, 50(1): 1-17.
|
[10] |
Bhattacharyya S, Varga J.Emerging roles of innate immune signaling and Toll-like receptors in fibrosis and systemic sclerosis[J]. Curr Rheumatol Rep, 2015, 17(1): 474.
|
[11] |
Melisi D, Frizziero M, Tamburrino A, et al. Toll-like receptor 9 agonists for cancer therapy[J]. Biomedicines, 2014, 2(3): 211-228.
|
[12] |
Aoshi T, Koyama S, Kobiyama K, et al. Innate and adaptive immune responses to viral infection and vaccination[J]. Curr Opin Virol, 2011, 1(4): 226-232.
|
[13] |
Blasius AL, Beutler B.Intracellular Toll-like receptors[J]. Immunity, 2010, 32(3): 305-315.
|
[14] |
Kim YM, Brinkmann MM, Paquet ME, et al. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes[J]. Nature, 2008, 452(7184): 234-238.
|
[15] |
Lee BL, Moon JE, Shu JH, et al. UNC93B1 mediates differential trafficking of endosomal TLRs[J]. Elife, 2013, 2: e00291.
|
[16] |
Ewald SE, Lee BL, Lau L, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor[J]. Nature, 2008, 456(7222): 658-662.
|
[17] |
Park B, Brinkmann MM, Spooner E, et al. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9[J]. Nat Immunol, 2008, 9(12): 1407-1414.
|
[18] |
Sepulveda FE, Maschalidi S, Colisson R, et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells[J]. Immunity, 2009, 31(5): 737-348.
|
[19] |
Ewald SE, Engel A, Lee J, et al. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase[J]. J Exp Med, 2011, 208(4): 643-651.
|
[20] |
Onji M, Kanno A, Saitoh S, et al. An essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing[J]. Nat Commun, 2013, 4: 1949.
|
[21] |
Mouchess ML, Arpaia N, Souza G, et al. Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation[J]. Immunity, 2011, 35(5): 721-732.
|
[22] |
Babdor J, Descamps D, Adiko AC, et al. IRAP+ endosomes restrict TLR9 activation and signaling[J]. Nat Immunol, 2017, 18(5): 509-518.
|
[23] |
Barton GM, Kagan JC, Medzhitov R.Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA[J]. Nat Immunol, 2006, 7(1): 49-56.
|
[24] |
Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide[J]. Nature, 2007, 449(7162): 564-569.
|
[25] |
吴翀, 丁国富, 周红. 抗人TLR9抗体对CpG寡核苷酸介导的人外周血单核细胞肿瘤坏死因子-α释放的影响[J]. 中国临床药理学与治疗学, 2006, 11(3): 324-327.
|
[26] |
Guerrier T, Pochard P, Lahiri A, et al. TLR9 expressed on plasma membrane acts as a negative regulator of human B cell response[J]. J Autoimmun, 2014, 51: 23-29.
|
[27] |
Rao DA, Gurish MF, Marshall JL, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis[J]. Nature, 2017, 542(7639): 110-114.
|
[28] |
Liu Y, Liu A, Iikuni N, et al. Regulatory CD4+ T cells promote B cell anergy in murine lupus[J]. J Immunol, 2014, 192(9): 4069-4073.
|
[29] |
Kohm AP, McMahon JS, Podojil JR, et al. Cutting edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+T regulatory cells[J]. J Immunol, 2006, 176(6): 3301-3305.
|
[30] |
Zelenay S, Demengeot J.Comment on “Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+T regulatory cells”[J]. J Immunol, 2006, 177(4): 2036-2037; author reply 2037-2038.
|
[31] |
Stephens LA, Anderton SM.Comment on “Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+T regulatory cells”[J]. J Immunol, 2006, 177(4): 2036; author reply 2037-2038.
|
[32] |
Wang Z, Xiao L, Shi BY, et al. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation[J]. Transpl Immunol, 2008, 19(1): 69-73.
|
[33] |
Game DS, Hernandez-Fuentes MP, Lechler RI.Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro[J]. Am J Transplant, 2005, 5(3): 454-464.
|